Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424).

MLA

Lightman, Sue, et al. “Re: Hughes et Al.: Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis (Ophthalmology. 2019;126:415-424).” Ophthalmology, vol. 126, no. 3, Mar. 2019, pp. e22–24. EBSCOhost, https://doi.org/10.1016/j.ophtha.2018.12.004.

APA

Lightman, S., Niederer, R., Sharma, S., Hooper, C., Tomkins-Netzer, O., Kramer, M., Damato, E. M., Peebo, B., & McCluskey, P. (2019). Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology, 126(3), e22–e24. https://doi.org/10.1016/j.ophtha.2018.12.004

Chicago

Lightman, Sue, Rachael Niederer, Srilakshmi Sharma, Claire Hooper, Oren Tomkins-Netzer, Michal Kramer, Erika Marie Damato, Beatrice Peebo, and Peter McCluskey. 2019. “Re: Hughes et Al.: Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis (Ophthalmology. 2019;126:415-424).” Ophthalmology 126 (3): e22–24. doi:10.1016/j.ophtha.2018.12.004.